HDAC6 and myeloproliferative disorder: Consequently, pharmacological inhibition of HDAC6 could represent an interesting therapeutic strategy in the treatment of myeloproliferative neoplasms, such as polycythemia vera (PV), characterized by the activating mutation JAK2V617F.